This study reveals the previously underappreciated roles of CD25 (IL-2 receptor subunit-α) in IL-2 biology and cancer immunotherapy and provides mechanistic insights into the rational design of more-effective IL-2-based therapeutic agents for cancer treatment.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018). A review article that presents the dual and opposing functions of IL-2.
Hernandez, R., Põder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614–628 (2022). A review article summarizing the different approaches to engineering IL-2 analogs.
[No authors listed]. Bempeg failure unlikely to affect other IL2 drugs. Cancer Discov. 12, 1604–1605 (2022). This news-in-brief article reports the clinical failure of an engineered IL-2.
Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022). This paper reports a new method of neoantigen-specific T cell receptor prediction.
Gide, T. N. et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. Cancer cell 35, 238–255 (2019). This paper reports predictive biomarkers of anti-PD-1 responses in patients with melanoma.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Wu, W. et al. IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat. Cancer https://doi.org/10.1038/s43018-023-00612-0 (2023).
Rights and permissions
About this article
Cite this article
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy. Nat Cancer 4, 1222–1223 (2023). https://doi.org/10.1038/s43018-023-00613-z
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00613-z
